OGI:TSX-OrganiGram Holdings Inc (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | TSX

Last Closing Price

CAD 1.53

Change

-0.05 (-3.16)%

Market Cap

CAD 0.45B

Volume

0.70M

Avg Analyst Target

CAD 2.61 (+70.26%)

Avg User Target

CAD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


OGI Stock Forecast & Price:
Based on the OrganiGram Holdings Inc stock forecasts from 6 analysts, the average analyst target price for OrganiGram Holdings Inc is CAD 2.61 over the next 12 months. OrganiGram Holdings Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of OrganiGram Holdings Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, OrganiGram Holdings Inc’s stock price was CAD 1.53. OrganiGram Holdings Inc’s stock price has changed by +10.07% over the past week, +17.69% over the past month and -50.80% over the last year.

About OrganiGram Holdings Inc (OGI:CA:TSX)

Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational canna ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-16 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
APHA:CA Aphria Inc

N/A

CAD4.44B 57.08 598.01
TLRY:CA Tilray Inc

-0.15 (-2.71%)

CAD2.98B 9.70 -13.19
BHC:CA Bausch Health Companies Inc

+0.06 (+0.74%)

CAD2.78B 38.45 10.18
WEED:CA Canopy Growth Corp

-0.06 (-1.22%)

CAD2.36B N/A -0.92
CRON:CA Cronos Group Inc

-0.01 (-0.23%)

CAD1.65B 46.76 -0.67
GUD:CA Knight Therapeutics Inc

+0.06 (+0.98%)

CAD0.70B 41.51 31.57
ACB:CA Aurora Cannabis Inc

-0.10 (-4.12%)

CAD0.69B 1,171.00 -0.54
HLS:CA HLS Therapeutics Inc

-0.01 (-0.08%)

CAD0.43B N/A 18.88
DHT-UN:CA DRI Healthcare Trust

+0.40 (+4.73%)

CAD0.36B 14.06 N/A
INCR-U:CA InterCure Ltd

-0.20 (-3.23%)

CAD0.29B 47.77 5.56

ETFs Containing OGI:CA

Symbol Name Weight Mer Price(Change) Market Cap
SEED:CA Evolve Marijuana Fund 0.00 % 0.75 %

N/A

CAD3.63M
HMMJ-U:CA Horizons Marijuana Life S.. 0.00 % 0.85 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -31.08% 66% D 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.08% 66% D 10% F
Trailing 12 Months  
Capital Gain -50.80% 63% D 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.80% 63% D 5% F
Trailing 5 Years  
Capital Gain -22.35% 73% C 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.35% 73% C 19% F
Average Annual (5 Year Horizon)  
Capital Gain 12.33% 91% A- 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.33% 91% A- 72% C-
Risk Return Profile  
Volatility (Standard Deviation) 77.17% 22% F 10% F
Risk Adjusted Return 15.97% 84% B 34% F
Market Capitalization 0.45B 81% B- 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 92% A- 99% A+
Price/Book Ratio 0.87 53% F 74% C
Price / Cash Flow Ratio -15.58 88% B+ 88% B+
EV/EBITDA -952.32 100% A+ 100% A+
Management Effectiveness  
Return on Equity -6.72% 75% C 23% F
Return on Invested Capital -20.49% 53% F 11% F
Return on Assets -4.73% 66% D 17% F
Debt to Equity Ratio 0.05% 81% B- 95% A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 5.56 44% F 36% F
Short Percent 3.91% 11% F 21% F
Beta 1.30 62% D- 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector